chronic lymphocytic leukaemia

News

Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.

News

Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.

News

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

Eli Lilly has revealed the data it hopes will take BTK inhibitor Jaypirca into frontline use for chronic lymphocytic leukaemia.

News

Eli Lilly's fast-growing Jaypirca has won a new FDA approval as an earlier treatment for relapsed/refractory chronic lymphocytic leukaemia.

News

AbbVie has turned to an award-winning documentary director to help it highlight the lives of people living with chronic lymphocytic leukaemia.